Published in Cancer J on November 08, 2004
Influence of clinical communication on patients' decision making on participation in clinical trials. J Clin Oncol (2008) 3.17
Increasing participation of cancer patients in randomised controlled trials: a systematic review. Trials (2006) 1.41
Barriers to therapeutic clinical trials enrollment: differences between African-American and white cancer patients identified at the time of eligibility assessment. Clin Trials (2012) 1.09
Translating research into practice: the role of provider-based research networks in the diffusion of an evidence-based colon cancer treatment innovation. Med Care (2012) 1.05
Removing barriers to participation in clinical trials, a conceptual framework and retrospective chart review study. Trials (2012) 0.94
A descriptive analysis of state legislation and policy addressing clinical trials participation. J Health Care Poor Underserved (2009) 0.83
Disparities in cancer clinical trials: an analysis of comprehensive cancer control plans. Prev Chronic Dis (2009) 0.82
Increasing primary care physician support for and promotion of cancer clinical trials. Hawaii J Med Public Health (2014) 0.79
Improving clinical trial accrual by streamlining the referral process. Int J Med Inform (2014) 0.77
Effect of state-mandated insurance coverage on accrual to community cancer clinical trials. Contemp Clin Trials (2012) 0.75
Evidence-based approaches to overcoming barriers to clinical trial accrual. Cancer J (2004) 0.75
Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med (2004) 23.44
Ways toward an early diagnosis in Alzheimer's disease: the Alzheimer's Disease Neuroimaging Initiative (ADNI). Alzheimers Dement (2005) 7.90
The Alzheimer's disease neuroimaging initiative. Neuroimaging Clin N Am (2005) 7.26
Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol (2008) 6.11
Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial. Lancet (2009) 5.82
Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023. J Clin Oncol (2008) 5.11
Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med (2006) 4.10
Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial. J Clin Oncol (2012) 3.92
Upregulation of choline acetyltransferase activity in hippocampus and frontal cortex of elderly subjects with mild cognitive impairment. Ann Neurol (2002) 3.84
Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia. J Clin Oncol (2008) 3.71
Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16. J Natl Cancer Inst (2006) 3.63
Combinatorial chemistry identifies high-affinity peptidomimetics against alpha4beta1 integrin for in vivo tumor imaging. Nat Chem Biol (2006) 3.22
Profiling of glycans in serum for the discovery of potential biomarkers for ovarian cancer. J Proteome Res (2006) 2.99
Aurora kinases as anticancer drug targets. Clin Cancer Res (2008) 2.92
Increased EGFR gene copy number detected by fluorescent in situ hybridization predicts outcome in non-small-cell lung cancer patients treated with cetuximab and chemotherapy. J Clin Oncol (2008) 2.85
Relevance of platinum-sensitivity status in relapsed/refractory extensive-stage small-cell lung cancer in the modern era: a patient-level analysis of southwest oncology group trials. J Thorac Oncol (2015) 2.80
Directing mesenchymal stem cells to bone to augment bone formation and increase bone mass. Nat Med (2012) 2.80
Natural history of stage I non-small cell lung cancer: implications for early detection. Chest (2007) 2.78
Current applications for prostate-specific antigen doubling time. Eur Urol (2008) 2.76
Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124. J Clin Oncol (2009) 2.73
Disease control rate at 8 weeks predicts clinical benefit in advanced non-small-cell lung cancer: results from Southwest Oncology Group randomized trials. J Clin Oncol (2008) 2.64
Genotyping and genomic profiling of non-small-cell lung cancer: implications for current and future therapies. J Clin Oncol (2013) 2.59
Phase II trial of pemetrexed plus bevacizumab for second-line therapy of patients with advanced non-small-cell lung cancer: NCCTG and SWOG study N0426. J Clin Oncol (2009) 2.54
The effect of surface charge on in vivo biodistribution of PEG-oligocholic acid based micellar nanoparticles. Biomaterials (2011) 2.45
Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: results of a multicenter phase II National Cancer Institute trial. J Clin Oncol (2007) 2.36
Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial. Lancet Oncol (2013) 2.29
The minimum element of a synthetic peptide required to block prostate tumor cell migration. Cancer Biol Ther (2006) 2.20
Impact of the year 2000 Medicare policy change on older patient enrollment to cancer clinical trials. J Clin Oncol (2005) 2.19
Evaluation of factors affecting awareness of and willingness to participate in cancer clinical trials. J Clin Oncol (2005) 2.10
Well-defined, reversible boronate crosslinked nanocarriers for targeted drug delivery in response to acidic pH values and cis-diols. Angew Chem Int Ed Engl (2012) 2.08
Concurrent cisplatin, etoposide, and chest radiotherapy in pathologic stage IIIB non-small-cell lung cancer: a Southwest Oncology Group phase II study, SWOG 9019. J Clin Oncol (2002) 2.07
Loss of tolerance in C57BL/6 mice to the autoantigen E2 subunit of pyruvate dehydrogenase by a xenobiotic with ensuing biliary ductular disease. Hepatology (2008) 2.05
A self-assembling nanoparticle for paclitaxel delivery in ovarian cancer. Biomaterials (2009) 2.04
A serum glycomics approach to breast cancer biomarkers. Mol Cell Proteomics (2006) 2.03
Morbidity, mortality, and technical factors of distal pancreatectomy. Am J Surg (2002) 2.03
Career flexibility and family-friendly policies: an NIH-funded study to enhance women's careers in biomedical sciences. J Womens Health (Larchmt) (2011) 2.01
From combinatorial chemistry to cancer-targeting peptides. Mol Pharm (2007) 1.98
Well-defined, size-tunable, multifunctional micelles for efficient paclitaxel delivery for cancer treatment. Bioconjug Chem (2010) 1.98
Consolidation docetaxel after concurrent chemoradiotherapy in stage IIIB non-small-cell lung cancer: phase II Southwest Oncology Group Study S9504. J Clin Oncol (2003) 1.97
Longitudinal changes in white matter disease and cognition in the first year of the Alzheimer disease neuroimaging initiative. Arch Neurol (2010) 1.94
Incidence of venous thromboembolism and the impact on survival in breast cancer patients. J Clin Oncol (2007) 1.92
Incidence of venous thromboembolism in the year before the diagnosis of cancer in 528,693 adults. Arch Intern Med (2005) 1.90
CCI-779 in metastatic melanoma: a phase II trial of the California Cancer Consortium. Cancer (2005) 1.89
A novel peptide-based encoding system for "one-bead one-compound" peptidomimetic and small molecule combinatorial libraries. J Am Chem Soc (2002) 1.87
Epidemiology of venous thromboembolism in 9489 patients with malignant glioma. J Neurosurg (2007) 1.83
Positron emission tomography and improved survival in patients with lung cancer: the Will Rogers phenomenon revisited. Arch Intern Med (2008) 1.79
Probiotics and immunity. J Gastroenterol (2009) 1.79
Simultaneous care: disease treatment and palliative care throughout illness. J Clin Oncol (2003) 1.79
Economic analysis of vinorelbine plus cisplatin versus paclitaxel plus carboplatin for advanced non-small-cell lung cancer. J Natl Cancer Inst (2002) 1.78
Palliative care for prison inmates: "don't let me die in prison". JAMA (2007) 1.77
"OA02" peptide facilitates the precise targeting of paclitaxel-loaded micellar nanoparticles to ovarian cancer in vivo. Cancer Res (2012) 1.75
Satisfaction with work-life balance and the career and retirement plans of US oncologists. J Clin Oncol (2014) 1.73
Carboplatin and Paclitaxel in combination with either vorinostat or placebo for first-line therapy of advanced non-small-cell lung cancer. J Clin Oncol (2009) 1.70
Therapeutic cancer targeting peptides. Biopolymers (2002) 1.70
Can patient coaching reduce racial/ethnic disparities in cancer pain control? Secondary analysis of a randomized controlled trial. Pain Med (2007) 1.66
Phase II study of Aflibercept (VEGF-Trap) in patients with recurrent or metastatic urothelial cancer, a California Cancer Consortium Trial. Urology (2010) 1.65
Burnout and career satisfaction among US oncologists. J Clin Oncol (2014) 1.64
Autophagy Blockade Sensitizes Prostate Cancer Cells towards Src Family Kinase Inhibitors. Genes Cancer (2010) 1.63
Pharmacodynamic separation of epidermal growth factor receptor tyrosine kinase inhibitors and chemotherapy in non-small-cell lung cancer. Clin Lung Cancer (2006) 1.61
Japanese-US common-arm analysis of paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a model for assessing population-related pharmacogenomics. J Clin Oncol (2009) 1.61
A phase II trial of vorinostat (suberoylanilide hydroxamic acid) in metastatic breast cancer: a California Cancer Consortium study. Clin Cancer Res (2008) 1.60
MRI predictors of cognitive change in a diverse and carefully characterized elderly population. Neurobiol Aging (2010) 1.56
A lack of default network suppression is linked to increased distractibility in ADHD. Brain Res (2009) 1.55
Thymoma-associated multiorgan autoimmunity: a graft-versus-host-like disease. J Am Acad Dermatol (2007) 1.54
Modern parathyroid surgery: a cost-benefit analysis of localizing strategies. Arch Surg (2002) 1.54
Polymorphisms and clinical outcome in recurrent ovarian cancer treated with cyclophosphamide and bevacizumab. Clin Cancer Res (2008) 1.53
A phase I study of veliparib in combination with metronomic cyclophosphamide in adults with refractory solid tumors and lymphomas. Clin Cancer Res (2012) 1.53
Tobacco smoking during radiation therapy for head-and-neck cancer is associated with unfavorable outcome. Int J Radiat Oncol Biol Phys (2010) 1.50
Epidermal growth factor receptor inhibition in lung cancer: status 2012. J Thorac Oncol (2013) 1.50
Well-defined, reversible disulfide cross-linked micelles for on-demand paclitaxel delivery. Biomaterials (2011) 1.50
A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer. Cancer Chemother Pharmacol (2009) 1.47
HER2-associated radioresistance of breast cancer stem cells isolated from HER2-negative breast cancer cells. Clin Cancer Res (2012) 1.47
Chemical xenobiotics and mitochondrial autoantigens in primary biliary cirrhosis: identification of antibodies against a common environmental, cosmetic, and food additive, 2-octynoic acid. J Immunol (2005) 1.47
Overcoming barriers to cancer clinical trial accrual: impact of a mass media campaign. Cancer (2008) 1.47
Phase II study of erlotinib in patients with malignant pleural mesothelioma: a Southwest Oncology Group Study. J Clin Oncol (2007) 1.46
Oblique-incidence reflectivity difference microscope for label-free high-throughput detection of biochemical reactions in a microarray format. Appl Opt (2007) 1.45
Heterogeneity of cognitive trajectories in diverse older persons. Psychol Aging (2010) 1.44
A multigene assay is prognostic of survival in patients with early-stage lung adenocarcinoma. Clin Cancer Res (2008) 1.43
Congo red and thioflavin-T analogs detect Abeta oligomers. J Neurochem (2007) 1.43
Venous thromboembolism in ovarian cancer. Gynecol Oncol (2007) 1.42
A novel size-tunable nanocarrier system for targeted anticancer drug delivery. J Control Release (2010) 1.42
Time from treatment to subsequent diagnosis of brain metastases in stage III non-small-cell lung cancer: a retrospective review by the Southwest Oncology Group. J Clin Oncol (2005) 1.41
Glycomic approach for potential biomarkers on prostate cancer: profiling of N-linked glycans in human sera and pRNS cell lines. Dis Markers (2008) 1.41
Identification of 2-nonynoic acid, a cosmetic component, as a potential trigger of primary biliary cirrhosis. J Autoimmun (2006) 1.41
Direct binding of integrin alphavbeta3 to FGF1 plays a role in FGF1 signaling. J Biol Chem (2008) 1.40
Phase I trial of edatrexate in advanced breast and other cancers. Cancer Invest (2002) 1.39
Confronting the brutal facts in health care. Am J Med (2005) 1.39
Bortezomib (PS-341) in relapsed or refractory extensive stage small cell lung cancer: a Southwest Oncology Group phase II trial (S0327). J Thorac Oncol (2006) 1.39
Lower osteopontin plasma levels are associated with superior outcomes in advanced non-small-cell lung cancer patients receiving platinum-based chemotherapy: SWOG Study S0003. J Clin Oncol (2008) 1.38
Toward a common therapeutic framework in castration-resistant prostate cancer: a model for urologic oncology and medical oncology interaction. Urol Oncol (2014) 1.38